

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IMPACT Therapeutics, Inc
南京英派藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT

**IMPACT THERAPEUTICS ANNOUNCES IMP3201
AS A PRECLINICAL CANDIDATE (PCC), A FIRST-IN-CLASS
CEACAM5-TARGETED DUAL-PAYLOAD ADC FROM ITS
PROPRIETARY DUAL-PAYLOAD ADC PLATFORM**

This announcement is made by IMPACT Therapeutics, Inc (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The Company is pleased to announce that IMPACT Therapeutics has nominated IMP3201 as a pre-clinical candidate (PCC), a novel first-in-class (FIC) CEACAM5-targeted dual-payload ADC. IMP3201 is the first PCC discovered by IMPACT Therapeutics using its proprietary branched linker dual-payload ADC technology platform.

IMP3201 is a CEACAM5-targeted, uniquely designed dual-payload ADC with Exatecan (TOPOi) and the Company’s proprietary ATR inhibitor (ATRi) at a defined and optimized molar ratio. By concurrently inducing DNA damage and blocking DNA damage repair pathways, the dual payload ADC generates strong synergistic anti-tumor effects and effectively overcomes tumor insensitivity and acquired resistance to conventional TOPOi-based ADC. IMP3201 shows significantly enhanced in-vitro and in-vivo anti-tumor activity as well as a favorable therapeutic window through precise targeting, stable circulation, and controlled payload release. The candidate will be developed for the treatment of gastrointestinal malignancies, including colorectal cancer, pancreatic cancer, gastric cancer and esophageal squamous cell carcinoma, addressing substantial unmet clinical needs.

CEACAM5, also known as Carcinoembryonic Antigen (CEA) or CD66e, is a highly glycosylated cell-surface glycoprotein. It plays a critical role in tumor progression and development by mediating tumor cell aggregation through homophilic/heterophilic binding, disrupting cell differentiation and polarity, promoting tumor metastasis, and inhibiting anoikis. CEACAM5 is significantly overexpressed in various epithelial-derived malignant tumors, including colorectal cancer, gastric cancer, pancreatic cancer, esophageal squamous cell carcinoma, and non-small cell lung cancer (NSCLC), whereas its expression remains highly restricted in normal adult tissues. Currently, CEACAM5-targeted antibody-drug conjugates (ADCs) utilizing single topoisomerase (TOPO) inhibitors, such as Merck’s Precem-TcT (M9140), have entered Phase 2/3 clinical trials and demonstrated preliminary anti-tumor activity in patients with heavily pretreated metastatic colorectal cancer.

This nomination represents IMPACT Therapeutics' first PCC from its proprietary dual-payload ADC platform, validating the platform's technical maturity and productivity. The company has established a comprehensive ADC portfolio covering both single-novel-payload and dual-payload platforms. The dual-payload ADC platform enables co-delivery of two synergistic payloads to overcome drug resistance and improve efficacy. Leveraging this versatile platform, the company will accelerate the development of next-generation ADCs and strengthen its competitive edge.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately develop, manufacture and/or commercialize IMP3201. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, July 27, 2026

As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.